APR 10, 2013
Systemic Pharmacologic Agents in Development for Uveitis: Voclosporine, Adalimumab, and AIN457
By Eric Suhler, MD
Subspecialty Day 2012: Uveitis
Uveitis
In this presentation from the 2012 Annual Meeting, Dr. Eric Suhler discusses evolving systemic therapy for uveitis including:
- Open-label studies including abatacept, tocilizumab, rituximab, and TNF blockers
- LX211 (voclosporin) and the Lux Uveitis Multicenter Investigation of a New Approach to Treatment (LUMINATE) studies
- Visual I, II, and III clinical trials
- Secukinumab studies
- IL-1 blockers